T
CBDG
vs
S&P 500
S&P 500
Over the past 12 months, CBDG has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +13% growth.
Stocks Performance
CBDG vs S&P 500
Performance Gap
CBDG vs S&P 500
Performance By Year
CBDG vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
THC Farmaceuticals Inc
Glance View
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona. The company went IPO on 2012-08-22. The firm through its subsidiary CBDual Biotechnology Corp., a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The firm is engaged cannabis formulations, edibles, and delivery systems of cannabis. The company manufactures and markets cannabis extract products made from cannabis. The firm's facility is located in Southern California. The company provides access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. The firm is focusing on the research of psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations.
